Search research articles
Contact Us
Filters
Showing results (51-60 of 62) with videos related to
Page
of 7
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 28, 2012
First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG
K Lindemann, R D Christensen, I Vergote, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 14, 2016
Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial
K Lindemann, G Kristensen, M R Mirza, et al.
Cell
|
June 18, 2003
Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal
Kirsten Lauber, Erwin Bohn, Stefan Martin Kröber, et al.
Gynecologic Oncology
|
January 22, 2022
Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis
A Poveda, S Lheureux, N Colombo, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
August 8, 2008
Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist
Ailsa J Frew, Ralph K Lindemann, Ben P Martin, et al.
JCI Insight
|
November 22, 2022
ATR represents a therapeutic vulnerability in clear cell renal cell carcinoma
Philipp Seidel, Anne Rubarth, Kyra Zodel, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 2, 2007
Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma
R K Lindemann, A Newbold, K F Whitecross, et al.
Cancer Discovery
|
December 18, 2012
The mTORC1 inhibitor everolimus prevents and treats Eμ-Myc lymphoma by restoring oncogene-induced senescence
Meaghan Wall, Gretchen Poortinga, Kym L Stanley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 5, 2023
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial
E Pujade-Lauraine, F Selle, G Scambia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2024
ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer
T Van Gorp, D Cibula, W Lv, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 62) with videos related to
Sort By:
Page
of 7
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 28, 2012
First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG
K Lindemann, R D Christensen, I Vergote, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 14, 2016
Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial
K Lindemann, G Kristensen, M R Mirza, et al.
Cell
|
June 18, 2003
Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal
Kirsten Lauber, Erwin Bohn, Stefan Martin Kröber, et al.
Gynecologic Oncology
|
January 22, 2022
Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis
A Poveda, S Lheureux, N Colombo, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
August 8, 2008
Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist
Ailsa J Frew, Ralph K Lindemann, Ben P Martin, et al.
JCI Insight
|
November 22, 2022
ATR represents a therapeutic vulnerability in clear cell renal cell carcinoma
Philipp Seidel, Anne Rubarth, Kyra Zodel, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 2, 2007
Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma
R K Lindemann, A Newbold, K F Whitecross, et al.
Cancer Discovery
|
December 18, 2012
The mTORC1 inhibitor everolimus prevents and treats Eμ-Myc lymphoma by restoring oncogene-induced senescence
Meaghan Wall, Gretchen Poortinga, Kym L Stanley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 5, 2023
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial
E Pujade-Lauraine, F Selle, G Scambia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2024
ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer
T Van Gorp, D Cibula, W Lv, et al.
Page
of 7